TSE:4507Pharmaceuticals
Does Shionogi’s Pediatric Fetroja sNDA Shift the Bull Case For Shionogi (TSE:4507)?
Shionogi recently announced that the U.S. FDA has accepted a Supplemental New Drug Application for Fetroja (cefiderocol) to treat pediatric patients with hospital-acquired and ventilator-associated bacterial pneumonia and complicated urinary tract infections caused by specific Gram-negative organisms, with a PDUFA action date set for February 23, 2027.
This regulatory step is important because it targets a clear treatment gap for children facing drug-resistant infections, potentially...